T2 Biosystems, Inc. updated revenue guidance for the year 2023. The company now expects full year total sepsis and related product revenue of $9.5 million to $10.5 million, representing growth of 13% to 25%, compared to 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.39 USD | +18.81% | +20.94% | -30.04% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.04% | 50.04M | |
+11.29% | 226B | |
+8.76% | 188B | |
+12.90% | 137B | |
+25.95% | 108B | |
+0.34% | 63.19B | |
+11.08% | 52.26B | |
+5.62% | 51B | |
+6.28% | 43.89B | |
+4.80% | 38.07B |
- Stock Market
- Equities
- TTOO Stock
- News T2 Biosystems, Inc.
- T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023